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Abstract
Background: Streptococcus pneumoniae is a leading cause of pneumonia, meningitis and sepsis in developing
countries, particularly among children and HIV-infected persons. Pneumococcal oropharyngeal (OP) or nasopharyngeal
(NP) colonization is a precursor to development of invasive disease. New conjugate vaccines hold promise for reducing
colonization and disease.
Methods: Prior to introduction of 10-valent pneumococcal conjugate vaccine (PCV10), we conducted a cross-sectional
survey among HIV-infected parents of children <5 years old in rural Kenya. Other parents living with an HIV-infected
adult were also enrolled. After broth enrichment, NP and OP swabs were cultured for pneumococcus. Serotypes were
identified by Quellung. Antimicrobial susceptibility was performed using broth microdilution.
Results: We enrolled 973 parents; 549 (56.4 %) were HIV-infected, 153 (15.7 %) were HIV-uninfected and 271 (27.9 %)
had unknown HIV status. Among HIV-infected parents, the median age was 32 years (range 15-74) and 374/
549 (68 %) were mothers. Pneumococci were isolated from 237/549 (43.2 %) HIV-infected parents and 41/153
(26.8 %) HIV-non-infected parents (p = 0.0003). Colonization with PCV10 serotypes was not significantly more
frequent in HIV-infected (12.9 %) than HIV-uninfected parents (11.8 %; p = 0.70). Among HIV-infected parents,
cooking site separate from sleeping area and CD4 count >250 were protective (OR = 0.6; 95 % CI 0.4, 0.9 and
OR = 0.5; 95 % CI 0.2, 0.9, respectively); other associations were not identified. Among 309 isolates tested from
all parents, 255 (80.4 %) were penicillin non-susceptible (MIC ≥0.12 μg/ml).
Conclusions: Prevalence of pneumococcal colonization is high among HIV-infected parents in rural Kenya. If young
children are the pneumococcal reservoir for this population, PCV10 introduction may reduce vaccine-type colonization
and disease among HIV-infected parents through indirect protection.
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Background
Streptococcus pneumoniae (pneumococcus) is a leading
cause of pneumonia, meningitis and sepsis among chil-
dren and adults in developing countries [1, 2]. Pneumo-
cocci colonize the upper respiratory tract, which is a
precursor state to pneumonia and invasive pneumococcal
disease (IPD). Transmission is common from person-to-
person through respiratory secretions, particularly within
families and other groups in which people are in close
contact [3–5]. Groups at highest risk for IPD after
pneumococcal acquisition include young children, the
elderly and immuno-compromised individuals such as
those infected with Human Immunodeficiency Virus
(HIV). Persons infected with HIV are approximately 25 to
50-fold more likely to develop IPD than are HIV-
uninfected persons [6–8].
While contact with young children is a well-established
risk factor for both pneumococcal colonization and
disease among all adults [9, 10], it is a particularly
important determinant of pneumococcal colonization
and disease among HIV-infected adults [11]. HIV-
infected adults are more likely to have disease
caused by serotypes associated with invasive disease
in children (e.g. 6B, 9 V, 14, 19 F, 23 F) than HIV-
uninfected adults [12], and HIV-infected mothers are
more likely to have disease caused by pediatric sero-
types than HIV-infected fathers [13, 14].
The introduction of the 7-valent pneumococcal conju-
gate vaccine (PCV7) among U.S. children in 2000 led to
a 94 % decrease in vaccine-type IPD among all chil-
dren <5 years from 1998–2003 [15]. It also led to
decreases in IPD among adults, including a 25 % decline
in all-serotype IPD incidence among HIV-infected adults
living with AIDS [7, 10]. This indirect or “herd” effect in
unvaccinated persons occurred because vaccinated chil-
dren were less likely to be colonized with PCV7 serotypes
and were therefore less likely to transmit them to unvac-
cinated persons [16, 17].
It is unknown whether the substantial indirect vaccine
effect seen among high-risk groups in the U.S. will also
be seen in African countries with high HIV seropreva-
lence. In January 2011, Kenya became the third African
country to introduce pneumococcal conjugate vaccine
into its national immunization program, and the first to
utilize the 10-valent formulation (PCV10) which ex-
panded coverage to include PCV7 serotypes (4, 6B, 9 V,
14, 18C, 19 F, 23 F) plus serotypes 1, 5, and 7 F. To
better understand the changes in pneumococcal ecol-
ogy among high risk groups before and after introduc-
tion of PCV10, we designed a study of pneumococcal
colonization among HIV-infected parents of young
children in a high HIV prevalence area of western
Kenya. In this report, we describe the baseline preva-
lence of pneumococcal colonization, including serotype




This study utilized two ongoing surveillance systems in
Asembo, western Kenya, to select and enroll partici-
pants—the western Kenya Health and Demographic Sur-
veillance System (HDSS) and Population-Based Infectious
Disease Surveillance (PBIDS) program. Both were estab-
lished through collaboration between the Kenya Medical
Research Institute (KEMRI) and Centers for Disease Con-
trol and Prevention (CDC) [18, 19]. The Asembo area is
mostly poor and is located in a rural province with one of
the highest HIV prevalence rates in Kenya. HDSS collects
demographic data on the population, including health sta-
tus, socioeconomic status, and education. In 2007, 14.9 %
of adults ages 15–64 years in Asembo were HIV-infected
[20]. Since 2005, residents of 33 HDSS villages within the
Asembo HDSS area have also been enrolled in PBIDS,
which measures morbidity in the community and at the
hospital [18]. Home-based counseling and testing (HBCT)
for HIV occurred throughout the Asembo area in 2008–
2009; these data were linkable to HDSS data and used to
identify HIV-infected persons for this study [20]. HIV sta-
tus was determined using two parallel HIV rapid tests, as
previously described [20]. Participants provided written
consent for any testing performed, and for linkage of HIV
results to their HDSS and PBIDS records.
Cross-sectional survey
We performed a cross-sectional survey among HDSS
residents who were parents of a child <5 years of age
and resided within the 33 PBIDS villages and 13 add-
itional adjacent HDSS villages in the Asembo area. We
used HDSS records to identify living compounds where
at least one HIV-infected parent of a child under 5 years
of age resided. To maintain confidentiality on HIV test-
ing status, HDSS village reporters approached the se-
lected compound and invited all parents of children
under 5 years of age (regardless of HIV status) residing
there to participate in the study. Interested persons were
referred to St. Elizabeth’s Mission Hospital clinic for
enrollment. Upon enrollment, data on household char-
acteristics, recent respiratory illness, smoke exposure,
cooking practices, and antibiotic usage were collected.
Additional demographic data and HIV-indicators (HIV
status, CD4 counts, use of highly active antiretroviral
therapy [HAART], and attendance at an HIV clinic) were
obtained through HDSS and PBIDS databases. For these
data, we attempted to obtain the most recent informa-
tion reported prior to sample collection. The survey was
conducted during October 29–December 23, 2009.
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Laboratory methods and definitions
Polyester-tipped swabs were swept over the posterior
oropharynx (OP) and tonsils, and calcium alginate swabs
were inserted into the posterior nasopharynx (NP) and
rotated 360°, as previously described [21]. Both NP and
OP swabs were collected from each participant. Swabs
were immediately placed in separate vials containing
skim milk-tryptone-glucose-glycerol (STGG) transport
medium and placed in a cool box as per World Health
Organization consensus methods [22]. Within 8 h, speci-
mens were vortexed and placed in a liquid nitrogen con-
tainer. The next morning specimens were transported
approximately 50 km to the KEMRI/CDC laboratory
and stored at −70 °C.
Pneumococcal isolation was conducted at the KEMRI-
CDC laboratory in Kisumu, Kenya by adding 200 μl of
NP-STGG 200 μl of OP-STGG from each individual in
an enrichment broth step following methods previously
described [23]. Any pneumococcal alpha-hemolytic colony
potentially identifiable as S. pneumoniae was subjected to
optochin susceptibility and bile solubility testing [24]. In
cases where more than one potential pneumococcal
colony type was identified per plate, representatives of
each colony type were subjected to testing. Pneumococcal
isolates were then transported on dry ice to the CDC
laboratory in Atlanta, GA for serotyping. Serotypes for the
pneumococcal isolates were obtained by latex agglu-
tination and Quellung reaction testing. Antimicrobial
susceptibility testing for commonly used antibiotics
was performed at KEMRI-CDC or CDC-Atlanta la-
boratories by broth microdilution (Trek Diagnostics,
Cleveland OH) according to the manufacturer’s in-
structions. Susceptibility was determined using Clin-
ical and Laboratory Standards Institute (CLSI) criteria
for minimum inhibitory concentration (MIC) from
2012 for non-beta lactams and 2007 for penicillin
(≥0.12 μg/ml), which we felt was most biologically
relevant for carriage where reduced susceptibility may
provide a selective advantage. Intermediate and resist-
ant isolates were designated as “non-susceptible”.
We categorized pneumococcal colonization by sero-
types present in either PCV10 (serotypes 1, 4, 5, 6B, 7 F,
9 V, 14, 18C, 19 F, 23 F) or the 13-valent PCV (PCV10
serotypes plus serotypes 3, 6A and 19A) vaccine formu-
lations. When multiple pneumococcal serotypes were
identified from a specimen, participants were classified
as colonized by a vaccine-serotype if at least one sero-
type was included in the vaccine. The isolate with the
highest MIC was used in reporting of antimicrobial re-
sistance when more than one isolate was detected.
Data management and analysis
Analyses were performed using SAS software (version
9.3; SAS institute). We categorized participants by HIV-
status (HIV-infected, HIV-uninfected, or HIV-unknown)
and used data on CD4 counts, history of use of HAART,
and last HIV-clinic attendance, when available. We de-
fined an ‘isolate’ as a pneumococcal strain of a particular
serotype from a participant. For example, if two colonies
were selected from a plate and had the same serotype,
this was considered 1 isolate; colonies of 2 different se-
rotypes were considered 2 isolates. We calculated a sero-
type diversity index (SDI) by dividing the number of
serotypes detected by the total number of isolates, such
that the maximum diversity score would be 1.00 and
least would be approaching 0. We performed univariable
and multivariable logistic regression to assess the associ-
ation of various risk factors with colonization among
participants, accounting for compound as a repeated
measure. Interactions with antibiotic usage, age, and
gender were explored. Odds ratios with 95 % confidence
intervals were calculated.
Ethical considerations
This study was approved by both KEMRI and CDC eth-
ical committees. All participants gave written informed
consent.
Results
We identified 772 HIV-infected parents of children <5 years
old living among 436 compounds in the HDSS database.
Of these, 549 (71.0 %) were enrolled in the study. The pri-
mary reason for non-enrollment in the study was out-
migration from the HDSS area. Persons enrolled did not
differ significantly from those not enrolled by gender, al-
though non-responders were slightly younger (median age
28 years, compared to 32 years among responders; p <
0.0001). An additional 424 parents (153 HIV-uninfected
and 271 of unknown HIV status) living with an HIV-
infected parent also participated in the study.
The age range among enrolled HIV-infected parents
was 15–74 years, and 68 % were mothers (Table 1). The
median number of children <5 years old living in each
household was 1 (range 1–4). A total of 141 (25.7 %) re-
ported a current cough, and 74 (13.5 %) reported a fever
within the previous 24 h. A large proportion reported
antimicrobial usage on the day of swabbing (n = 169,
30.8 %), the majority of which included cotrimoxazole
(161 of 169, 95.2 %). Among 200 parents for whom de-
tails on HIV indicators were available, 106 (53.8 %) were
enrolled at an HIV care and treatment clinic, 23 (11.6 %)
were on HAART, and 44 (22.0 %) had CD4 counts <250.
Pneumococcal colonization was 38.6 % among all par-
ticipants (Table 2), although prevalence was significantly
higher among HIV-infected parents (43.2 %) compared
to HIV-uninfected parents (26.8 %) living in the same
compounds (p = 0.0003). Colonization with PCV10 sero-
types was not significantly more frequent among HIV-
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infected (12.9 %) than HIV-uninfected parents (11.8 %;
p = 0.70). Among pneumococcal colonizers, the propor-
tion of isolates that were PCV10 serotypes was lower
among HIV-infected parents (30.0 %) than among HIV-
uninfected parents (43.9 %), but the difference was not
statistically significant (p = 0.08).
We detected 35 different serotypes from 242 isolates
among HIV-infected parents; five (0.9 %) individuals
carried 2 serotypes each. Although fewer numbers of
serotypes were detected among HIV-uninfected parents
(n = 16), the serotype diversity index (SDI) was higher
overall when compared to HIV-infected parents (0.39
compared to 0.14) (Table 2). Serotypes 3 (11.2 %), 16 F
(7.9 %), and 19 F (7.4 %) were the most common isolates
detected among HIV-infected parents (Fig. 1). No
significant differences in colonization with specific sero-
types was observed with the exception of serotype 19 F,
which was observed less frequently among HIV-infected
parents than HIV-uninfected parents (7.4 % vs
22.0 %; p = 0.003).
On multivariable analysis, high CD4 count was associ-
ated with significant decrease in colonization among
HIV-infected persons (Table 3). HIV-infected parents
with CD4 count ≥250 were less likely to be colonized
than those with lower CD4 counts (OR = 0.5; 95 % CI
0.2, 0.9). We also observed a protective effect of cooking
location being separate from sleeping location (OR = 0.6;
95 % CI 0.4, 0.9). We did not observe a significant asso-
ciation between colonization and smoking tobacco, the
number of children <5 years old in the home, the num-
ber of children attending school, the number of people
living in the compound, wealth quintile, type of cooking
fuel used, or self-reported fever within 24 h of sample
Table 1 Characteristics of HIV-infected parents of children <5 years
old in a survey of Streptococcus pneumoniae colonization in Western
Kenya (n= 549)a
Characteristic N (%)
Female gender 374 (68.1)
Age, median years (range) 32 (17–74)
< 30 years 188 (34.3)
30–39 years 269 (48.9)
> =40 years 92 (16.8)
Wealth quintileb




5 least poor 76 (26.8)
Currently employed 112 (20.6)
Number of years living in Asembo, median (range) 14 (0–73)
Number of compounds 460
Number of people in compound, median (range) 8 (1–38)
Median number of rooms used for sleeping 1 (1–6)





≥ 3 36 (6.6)




≥ 1 482 (87.8)
Recent illness
Current cough 141 (25.7)
Cough within 30 days 171 (31.3)
Pneumonia within 30 days 16 (2.9)
Fever within 24 hours 74 (13.5)
Fever within 30 days 171 (31.2)
Smoke exposure
Smokes tobacco 29 (5.3)
Tobacco smoke in the home 99 (18.2)




Area used for cooking
Same area used for sleeping 243 (44.3)
Dedicated separate building 235 (42.8)
Outside the house 45 (8.2)
Within the house, separate room 26 (4.7)
Table 1 Characteristics of HIV-infected parents of children <5 years
old in a survey of Streptococcus pneumoniae colonization in Western
Kenya (n= 549)a (Continued)
Antibiotic used
Use of any antibiotic within 7 days 313 (57.0)
Current use of any antibiotic 169 (30.8)
Current use of cotrimoxazole 161 (29.3)
Attends HIV clinice 106 (53.8)
HAART usee 23 (11.6)
CD4 count, median (range)e, f 445 (21–1378)
< 250 44 (21.9)
250–499 71 (35.3)
> 500 86 (42.8)
aPercentages reflect missing data
bWealth indices categorized into five quintiles: 1 (Poorest) to 5 (Least Poor)
cIncludes gas, kerosene, paraffin, and dung
dCurrent use refers to the day of interview
eData available for 201 respondents
fNumber of days since most recent CD4 count ranged from 166 before date of
interview to 840 days after (median 394 days before date of interview)
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collection. HIV infected parents were 2.1 times more
likely to be colonized than HIV-uninfected parents
(95 % CI 1.44, 3.03; data not shown), controlling for
other factors. We did not see any other differences in
colonization risk factors by HIV status. Interactions with
gender or amoxicillin use (current, within 7 days, or
within 30 days of sample collection), gender were also
not observed. Although age less than 40 years was pro-
tective in univariable analyses (OR = 0.6; 95 % CI 0.4,
0.9), this did not hold true in multivariable models.
Among 309 isolates tested for antimicrobial resistance
among all parents enrolled, a large proportion were non-
susceptible to one or more antibiotics: 308 (99.0 %) to
cotrimoxazole, 255 (80.4 %) to penicillin, and 78 (24.7 %)
to tetracycline (Tables 4 and 5). For other antibiotics
(levofloxacin, ceftriaxone, chloramphenicol, erythromycin,
clindamycin), the proportion non-susceptible was 0–
1.3 %. Antimicrobial susceptibility patterns were similar
across parent groups; although a greater proportion of the
isolates carried by HIV-infected parents were non-
susceptible to penicillin (83.4 %) when compared to iso-
lates from HIV-negative parents (67.7 %), this difference
was not statistically significant (p = 0.09; data not shown).
Most of the penicillin non-susceptible isolates were inter-
mediately resistant (MICs 0.12–1.0 μg/ml) rather than
fully resistant (≥2 μg/ml) to penicillin.
Discussion
PCV introduction in Africa has accelerated in recent
years, yet few published data document the baseline
prevalence of pneumococcal disease or colonization
among groups not targeted to receive vaccine, particularly
adults with HIV infection. The 43.2 % pneumococcal
colonization rate that we observed among HIV-infected
adults is similar to a previous study conducted in Kenya
among HIV clinic attendees (34.6 %) [25], but higher than
in studies conducted among HIV clinic attendees in
Uganda (18.0 %), mineworkers in South Africa (8.8 %),
and mothers of young infants in both South Africa
(20.2 %) and Zambia (11.4 %) [26–29]. The overall
colonization rate of 38.6 % observed among our partici-
pants is also higher than those reported among adults
with unspecified HIV status in Nigeria and the Gambia,
where 26 % of adults >18 years of age and 21 % of mothers
of 12-month-old infants were colonized, respectively [5,
30]. These variations may be partially explained by the
broth enrichment step used in this study, which was not
done in other studies from Africa. We used broth enrich-
ment before plating because it has been shown to increase
recovery of pneumococci from respiratory specimens [23].
In addition, all participants in our study were parents
of young children who live together in the same com-
pound, which may result in frequent transmission of
pneumococci. Other unspecified differences in the
populations studied in other African pneumococcal
colonization studies (e.g. recent illness or tobacco
smoke exposure) may also have contributed to the
differences observed in colonization rates. The high
colonization rate among our participants with un-
known HIV status (35.8 %) suggests that undocu-
mented HIV-infection may have been common among
adults in this group. Two groups known to be at
Table 2 Pneumococcal colonization among parents of children <5 years of age living in the same compound in Western Kenya, by
HIV-status (N = 973)
HIV- Infected only HIV-uninfected only HIV-unknown only All Participants
N (%) N (%) N (%) N (%)
Number of participants 549 153 271 973
Pneumococcal colonization, any typea 237 (43.2) 41 (26.8) 97 (35.8) 375 (38.5)
PCV10 type only 71 (12.9) 18 (11.8) 26 (9.6) 115 (11.8)
PCV13-type only 108 (19.7) 24 (15.7) 44 (16.2) 176 (18.1)
Total number of isolates detectedb 242 41 98 381
Number of different pneumococcal serotypes detected per personc,a
0 312 (56.8) 112 (73.2) 174 (64.2) 598 (61.4)
1 232 (42.3) 41 (26.8) 96 (35.4) 369 (38.0)
2 5 (0.9) 0 1 (0.4) 6 (0.6)
Total number of different pneumococcal serotypes detectede 35 16 30 41
Serotype diversity indexd,e 0.14 0.39 0.31 0.11
ap-value comparing HIV-infected compared to HIV-uninfected <0.001
bAny pneumococcal colony suspected of being alpha-hemolytic was selected for identification by susceptibility to optochin and bile solubility. In some cases,
more than one colony was identified per plate
cNo participant had >2 serotypes identified
dSerotype diversity index = total number of different pneumococcal serotypes detected divided by total number of isolates detected; Maximum diversity is 1.0 and
least diversity is 0
eDoes not include non-typeable isolates: HIV-infected (1), HIV-uninfected (2), HIV-unknown (3)
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higher risk of HIV are those who refused HIV testing and
those who were recent in-migrants to the study area. [31]
In this study HIV-infected parents were over two
times more likely to be colonized with pneumococci
than HIV-uninfected parents living in compounds with
an HIV-infected parent, when adjusting for other risk
factors. Because the mechanism of mucosal protection
against pneumococcal colonization is T-cell dependent,
HIV-infected persons with low CD4 counts may be at
highest risk for colonization and consequently for inva-
sive disease. CD4 counts less than 350 have been associ-
ated with increased risk of invasive disease in some
studies [6]; however, the link to colonization is less well
established [28, 29, 32]. No differences in colonization
prevalence by CD4 count were previously found among
HIV-infected adults in studies conducted in Kenya,
Brazil, and South Africa [25, 29, 33]. We found HIV-
infected parents with counts ≥250 to be somewhat pro-
tected from pneumococcal colonization. Although our
data were limited, we did not see a protective effect with
usage of HAART or attendance at an HIV clinic among
HIV-infected parents, which has been described before
[33]. Besides HIV infection, we also observed a signifi-
cant association between pneumococcal colonization
and cooking location where persons who described
cooking in an area separate from their sleeping area
were less likely to be colonized. Exposure to indoor air
pollution has been linked to adverse health outcomes in-
cluding pneumonia in the developing world [34] how-
ever the relationship with pneumococcal colonization is
less well established [35, 36]. We did not observe an as-
sociation between colonization and other established risk
factors for pneumococcal carriage including age, tobacco
smoke exposure, or the number of children <5 years in
the home [37, 38].
We detected 41 different serotypes in this rural Ken-
yan population, with a greater degree of diversity ob-
served among HIV-uninfected compared to HIV-
infected participants. This finding is consistent with the
greater diversity of invasive serotypes observed among
HIV-uninfected compared to HIV-infected adults in
South Africa [12] and will have implications for under-
standing changes in pneumococcal ecology and serotype
replacement after vaccine introduction [39]. The most
frequent colonizing serotypes observed among HIV-
infected parents in our study (3, 16 F, 19 F, 23 F) are
similar to findings from other surveys conducted among
HIV-infected adults in Nigeria, South Africa, and
Uganda [26–28] and among HIV-infected children in
Kenya and Tanzania [35, 36]. HIV-infected parents were
slightly more frequently colonized with PCV10-type and
PCV13-type pneumococci than HIV-uninfected parents,
although this difference was not statistically significant.
The baseline colonization rate among these groups will
be important to understanding the impact of vaccine
introduction in Kenya and will complement data on in-
vasive disease as it becomes available. The effect of
PCV10 introduction on the prevalence of serotypes 3
and 19A will be particularly important. In our study
serotype 3 was the most frequently carried serotype,
Fig. 1 Serotypes associated with pneumococcal colonization among parents of children under 5 years old living in the same compound in rural
Kenya, by HIV status (n = 381). *p-value comparing HIV-infected compared to HIV-uninfected <0.01 for serotype 19 F
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Table 3 Factors associated with pneumococcal colonization among HIV-infected parents of children <5 years old Kenya (N = 549)
Colonized Not Colonized OR (95 % CI)a
N = 237 N = 311
N (%) N (%)
Recent Illness
No fever within 24 hours 199 (84.0) 274 (88.4) referent
Self-reported fever within 24 hours 38 (16.0) 36 (11.6) 1.5 (0.9, 2.6)
Number of children <5 years old in the home
1 145 (61.2) 182 (58.5) referent
2 77 (32.5) 108 (34.7) 0.9 (0.6,1.3)
> 2 15 (6.3) 21 (6.8) 0.9 (0.5, 1.9)
Number of children in school
0 24 (10.1) 43 (13.8) referent
≥ 1 213 (89.9) 268 (86.2) 1.6 (0.9, 2.6)
Cooking location
Same as sleeping area 122 (51.5) 120 (38.6) referent
Other location separate from sleeping area 115 (48.5) 191 (61.4) 0.6 (0.4, 0.9)
Tobacco smoke exposureb
No smoker in the household 190 (81.2) 255 (82.2) referent
Smoker in the household 44 (18.8) 55 (17.8) 1.1 (0.7, 1.6)
Multiple Correspondence Analysis (MCA) quintileb, c
< 3 40 (31.5) 42 (26.7) referent
≥ 3 87 (68.5) 115 (73.3) 0.8 (0.5, 1.4)
CD4 Countb
CD4 < 250 25 (28.7) 19 (16.8) referent
CD4≥ 250 62 (71.3) 94 (83.2) 0.5 (0.2, 0.9)
HAARTb
No or unknown HAART use 76 (88.4) 100 (88.5) referent
HAART use 10 (11.6) 13 (11.5) 1.1 (0.5, 2.4)
aAdjusted for compound as a repeated measure, amoxicillin use within 7 days, age, and gender
bPercentages reflect missing data
cWealth indices categorized into five quintiles: 1 (Poorest) to 5 (Least Poor)
Table 4 Antimicrobial susceptibility of 309 pneumococcal isolates obtained from nasopharyngeal and oropharyngeal swabs
collected from 375 parents of children under 5 years of age in Western Kenya, by antiobiotic.
Antibiotic Susceptible Intermediate Resistant
Break-pointa N (%) Break-point N (%) Break-point N (%)
Penicillin ≤0.06 60 (19.4) 0.12-1 249 (78.6) ≥2 6 (1.9)
Chloramphenicol ≤4 305 (98.7) n/a n/a ≥8 4 (1.3)
Levofloxacin ≤2 312 (100) 4 0 ≥8 0
Erythromycin ≤0.25 305 (98.7) 0.5 1 (0.3) ≥1 3 (1.0)
Ceftriaxone ≤1 309 (100) 2 0 ≥4 0
Tetracycline ≤2 232 (75.3) 4 12 (3.9) ≥8 64 (20.8)
Cotrimoxazole ≤0.5/9.5 3 (1.0) 1/19–2/38 13 (4.2) ≥4/76 291 (94.8)
Clindamycin ≤0.25 308 (99.7) 0.5 0 ≥1 1(0.3)
aBreakpoints defined using Clinical and Laboratory Standards Institute (CLSI) guidelines 2007 for penicillin and 2012 for all other antibiotics
n/a not applicable
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although it is not covered by PCV10. Serotype 19A, also
not included in PCV10, was not detected in our study
but increased in some countries after PCV7 introduction
[40–43]. Still, as early data documenting the impact
of PCV10 on invasive disease among Kenya children
are becoming available [44], the potential for indirect
impact of the vaccine on pneumococcal colonization
and disease among non-vaccinated groups appears
promising. In the U.S., HIV-infected persons experi-
enced a 91 % drop in vaccine-type IPD after vaccine
introduction [7].
Our study had several potential limitations. Conduct-
ing the study over an 8-week period might only provide
a snapshot of colonization in this population, as
pneumococcal disease is transient and has been shown
to vary by season in some studies [35, 45] though
not others [46]. Second, much of our HIV-related
data pre-dated enrollment in the carriage study by
over 1 year which may have resulted in misclassifica-
tion, as HIV-uninfected may have become HIV-
infected during the time since their negative test. In
the Asembo area, the HIV incidence is estimated to
be approximately 1.2 % per year [personal communi-
cation, KEMRI/CDC]. Similarly, data on CD4 counts
may have been inaccurate as these are also time-
sensitive and can change over the course of HIV in-
fection and with use of HAART.
Conclusions
Characterizing the direct effect of PCV among children
targeted to receive vaccine, and assessing the indirect
vaccination effect among high-risk groups in Kenya will
have important policy implications in Africa. Because
HIV-infected persons have an impaired immune re-
sponse to polysaccharide vaccine, and conjugate vaccines
are not yet approved for their use in adults in most
countries [47, 48], the indirect effects of PCV introduc-
tion in Kenya will be critical in preventing disease in this
group.
Sustaining long term funding for vaccination programs
in early-adopting countries like Kenya and encouraging
other countries to adopt PCV will require demonstration
of vaccine impact. More potential factors may lead to a
different herd effect with introduction of PCV in Africa
than in high-income countries, including a potentially
lower rate of vaccine coverage, different socio-economic
conditions, and a variety of additional factors which
could influence the immunologic responses or protective
effect among vaccinated children (e.g. younger target
age-group, and higher prevalence of malaria and
malnutrition) [1, 49]. The baseline data presented in
this report will be compared with ongoing analyses
of pneumococcal carriage rates in HIV infected par-
ents over three years following introduction of
PCV10 in infants in Kenya. Once this investigation
is completed, the findings will contribute to a grow-
ing body of data on PCV impact that will be critical
for decision-making regarding sustained pneumococ-
cal immunization in Africa.
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(serotypes 1, 3, 4, 5, 6A, 6B, 7 F, 9 V, 14, 18C, 19A, 19 F, 23 F)
aNo serotype 5 isolates were detected
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